Physician profile
Datinder Deo
NPI 1952422917
$4,477.20
in general payments reported to CMS, 2019-2025
21 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $56.38 · 2022: $2,136 · 2023: $1,439 · 2024: $316 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,400 · Food and Beverage: $398 · Education: $65.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,400.00 |
| Food and Beverage | $397.72 |
| Education | $65.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $3,415.40 | 2019-2023 | |
| Travere Therapeutics, INC. | $176.55 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $117.10 | 2019-2024 | Farxiga |
| Vifor Pharma, INC. | $89.24 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.96 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $72.15 | 2019-2024 | Jynarque |
| Amgen INC. | $71.96 | 2022-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $69.59 | 2024-2025 | |
| Novo Nordisk INC | $68.26 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Enterprises LLC | $44.46 | 2019 | |
| Akebia Therapeutics INC | $43.92 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $39.90 | 2019-2025 | Velphoro |
| Pfizer INC. | $37.40 | 2019 | |
| Opko Pharmaceuticals, LLC | $27.73 | 2019-2022 | |
| Horizon Therapeutics Plc | $24.00 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $20.72 | 2024 | Korlym |
| Baxter Healthcare | $20.15 | 2019 | |
| Genentech USA, INC. | $17.43 | 2019 | |
| Ardelyx, INC. | $17.01 | 2023 | Ibsrela |
| Calliditas Therapeutics US INC. | $14.43 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Datinder Deo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.